Download this assay page in pdf format.
Specimen Type: Serum
Optimum Volume: 1.0 mL
|4 days||9 months||1 year|
Reporting units: nmol/L
Biological or Clinical Significance:
Structural collagens such as types I and II that are present in bone and cartilage, respectively, are crosslinked both within their α-chains and between adjacent molecules to provide rigidity and strength to the resulting collagen fibril. In bone and cartilage, pyridinoline (PYD), a trifunctional pyridinium crosslink, forms between specific hydroxylysine residues within the telopeptide regions of one collagen molecule and within the helical region of an adjacent collagen molecule. When bone or cartilage collagen is degraded, PYD is released into circulation and excreted in the urine.
In humans, the total pool of urinary PYD is approximately 45% free, while the remaining fraction is bound to oligopeptides ranging from small linear peptides to very large crosslinked structures in excess of 10,000 Da. The proportion of free to total crosslinks appears to be constant in healthy individuals and those with metabolic bone diseases or arthritis conditions, thus providing the rationale for measuring free PYD.
In rheumatoid arthritis, destruction of cartilage and other collagen-containing joint tissue may contribute to increased levels of PYD.Deoxypyridinoline (DPD), a pyridinium crosslink differing from PYD only by the absence of a hydroxyl group, is essentially bone specific. The ratio of PYD:DPD in bone of approximately 4:1 is closely concordant with the ratio observed in urine of healthy individuals and those with metabolic bone diseases or osteoarthritis in spite of a much higher PYD:DPD ratio in non-bone tissues. This suggests that both crosslinks reflect bone resorption under these conditions.
Principle of Test Method:
The PYD assay is a solid-phase ELISA that employs the quantitative competitive enzyme immunoassay principle.